Peptides are having a moment. Or maybe a reckoning — depending on who you ask.
Imports of hormone and peptide compounds from China roughly doubled to $328 million in the first three quarters of 2025, compared to $164 million in the same period of 2024. MIT Technology Review ran a feature titled "Peptides are everywhere." NPR, CNN, and STAT News all published deep dives within weeks of each other. At Superpower, a health-tech startup in SF, employees reportedly get free peptide shots on Fridays.
So what's actually going on?
Peptides are short chains of amino acids — anywhere from 2 to about 40 amino acids linked together. Anything longer is technically a protein. Your body makes thousands of them naturally: insulin is a peptide, so is oxytocin, so are the GLP-1 hormones behind Ozempic and Mounjaro.
They work as signaling molecules — essentially messengers that tell your cells what to do. Different peptides target different pathways: some regulate inflammation, others trigger growth hormone release, others modulate immune function.
The ones driving today's hype are synthetic versions of naturally occurring peptides, or in some cases, fragments of proteins that don't exist in nature as standalone molecules. The idea: if your body's own peptides decline with age, maybe supplementing them can restore function.
BPC-157 (Body Protection Compound-157) is the poster child. A 15-amino-acid fragment first isolated from human gastric juice in 1992 by Predrag Sikiric at the University of Zagreb. In animal studies, it shows remarkable healing properties — tendon repair, gut protection, anti-inflammatory effects. But here's the catch: BPC-157 has never been tested in a controlled human clinical trial. The amino acid sequence doesn't even appear in the human genome — the parent protein may be produced by gastric microbes, not human cells.
GHK-Cu (copper peptide) is used topically for skin regeneration and wound healing. It has more human data than most, with studies showing collagen synthesis and skin remodeling effects — which is why you'll find it in high-end skincare.
CJC-1295 and Ipamorelin are growth hormone secretagogues — they stimulate your pituitary gland to release more growth hormone. Popular in anti-aging clinics for claims around recovery, body composition, and sleep quality. Some human data exists, but mostly in small studies.
Thymosin alpha-1 is an immune modulator. Unlike most peptides on this list, it's actually an approved drug in several countries (not the US) for hepatitis B and C. It has the most legitimate clinical backing of the "longevity peptides."
Three forces converged.
First, GLP-1 drugs proved that peptide therapies could be both wildly effective and commercially massive — Ozempic and Mounjaro normalized the concept of injectable peptides for millions of people.
Second, the biohacking and longevity communities adopted peptides early and amplified them through social media. Influencer "stacks" like the "wolverine stack" for muscle growth and the "glow protocol" for skin health gave peptides a consumer identity they never had.
Third, the political landscape shifted: RFK Jr., now HHS Secretary, publicly promised to "end the FDA's war on peptides" — putting regulatory reform directly on the table.
Between October 2023 and December 2024, the FDA banned 17 peptidesfrom being compounded by US pharmacies, placing them in "Category 2" — meaning they're deemed to have safety concerns and cannot be prepared by compounding pharmacies. BPC-157, AOD-9604, and several others landed on this list.
The result? A gray market. Vials labeled "for research use only" are sold openly online. Testing of nearly 450 samples of BPC-157 from 64 vendors found purity ranging from 82% to 100% — and some vials didn't contain BPC-157 at all. In 2025, two women were hospitalized and placed on ventilators after receiving peptide injections at a longevity conference in Las Vegas.
The FDA reclassification expected in 2026 could change the landscape significantly — but whether that means more access or more chaos depends entirely on execution.
The science behind peptides is real and worth watching. Insulin was a peptide. GLP-1 drugs are peptides. The mechanism of action for compounds like BPC-157 is biologically plausible.
But "biologically plausible" and "proven safe and effective in humans" are separated by billions of dollars and years of clinical trials. Right now, the peptide market is the Wild West. The demand is running years ahead of the evidence.
If you're considering peptides, the distinction that matters isn't "natural vs. synthetic" — it's "tested in humans vs. tested in rats." Most of the popular ones are still firmly in the second category.
Gilead just bet $7.8 billion that CAR-T cell therapy is the future of cancer treatment. The pharma giant is acquiring Arcellx to take full control of anito-cel, a next-generation CAR-T therapy for multiple myeloma. FDA decision expected December 2026. Gilead paid a 68% premium — they're not hedging. The real signal: big pharma is consolidating cell therapy, not just exploring it.
The European Health Data Space regulation officially applies from March 26, 2026. EHDS creates a unified EU framework for sharing and reusing electronic health data across 27 member states. Member states have two years to set up digital health authorities. First priority data categories — patient summaries, e-prescriptions — must be exchangeable across all EU countries by March 2029. For anyone building in European healthtech, this is the infrastructure layer.
Hims & Hers is acquiring Eucalyptus to build a global consumer health platform. The US telehealth company is expanding beyond North America by buying the Australian-based health company. This follows their aggressive move into GLP-1s and positions them as one of the first consumer health platforms with genuine international reach. The playbook: own the direct-to-consumer relationship, then expand the menu.
For the builders
Pear VC just published their 2026 Request for Startups — and it's worth reading even if you're not raising from them. Their health-adjacent categories include AI-native clinical workflows, infrastructure for value-based care, and consumer health tools that integrate with provider systems. What's notable is what's absent: no mention of general wellness or biohacking. The smart money is still betting on healthcare delivery infrastructure, not consumer optimization. If you're building in healthtech and trying to calibrate where institutional capital is flowing versus consumer enthusiasm, this is a useful temperature check.
"Peptides are everywhere. Here's what you need to know." — MIT Technology Review's comprehensive look at the science, the hype, and the regulatory void. The best single overview available.
"BPC-157: The peptide with big claims and scant evidence" — STAT News on the most popular peptide's origins in a Croatian lab and the gap between animal data and human claims. Uncomfortable reading for true believers.
Three resources if you want to go deeper: The Protocole is building what might be the most comprehensive peptide education platform out there — protocol design, dosing frameworks, sourcing guides. Longevity Files has a solid "New to Peptides? Start Here" primer. And if you want the bear case, MASS Research Review's "The Peptide Problem" systematically dismantles the evidence gap. Save all three.
